An interventional study of placebo beverage and electrolyte beverage in Dehydration, Menstruation and Pre-menopause, sponsored by PepsiCo Global R&D. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by PepsiCo Global R&D (part of PepsiCo, Inc.) · Not applicable, Interventional, and Other
Female life stages including premenopausal, perimenopausal, postmenopausal, are characterized by changing concentrations and patterns of hormones. The premenopause stage represents the reproductive years with normal menstrual cycles lasting between 21-35 days. The perimenopause stage is the beginning of the menopause transition and can last up to 10 years. During this transition, menstrual cycles become longer and irregular in length (7 days or longer). After 12 consecutive months with no period, the transition is complete into the postmenopause stage.
Hormones that change across the lifespan are known to influence systems that regulate thirst, fluid balance, and sodium balance. Yet, fluid balance across life stages remains poorly understood, with no direct comparisons across all three life stages. The purpose of this study is to evaluate the effect of female life stage on rehydration with water and electrolyte solution after overnight fast and fluid restriction
201 studies on the registry are indexed under Dehydration; 28 are open to participants now.
This study's planned enrollment of 72 is above the median of 43 across 145 interventional studies indexed under Dehydration.
Browse Dehydration studies →PepsiCo Global R&D is the lead sponsor of 103 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sex assigned female at birth.
Premenopausal:
Perimenopausal:
:
Not currently taking medications known to influence fluid balance (e.g., diuretics, laxatives, weight loss agents, or other relevant medications) or the hypothalamus-pituitary-gonadal axis (e.g., ovulation induction agents, gonadotropins, IVF stimulation medications, or other relevant medications)
o See appendix 13.8 for list of medications, drugs, and/or medical conditions that may impair cognitive functioning, alter physiological responses relevant to the study outcomes, or increase the risk associated with participation.
For visit 2 and 4:
Exclusion Criteria:
Currently pregnant or breastfeeding
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: placebo beverage
Other: electrolyte beverage
333 mL aliquots 3 times for a total of 1 L over a 30 min period. Time 0 begins post-dose.
333 mL aliquots 3 times for a total of 1 L over a 30 min period. Time 0 begins post-dose. Beverage matched to placebo for color and flavor.
Fluid Balance
calculated as change in nude body mass from baseline (%)
Time frame: Change from baseline, 4 hours
Fluid Balance
calculated as change in nude body mass from baseline (g)
Time frame: Change from baseline, 4 hours
Urine Mass
g
Time frame: Change from baseline, 4 hours
Urine Specific Gravity
au
Time frame: Change from baseline, 4 hours
Urine Osmolality
mosmol/kg
Time frame: Change from baseline, 4 hours
Fluid Retention
Percentage (%)
Time frame: Change from baseline, 4 hours
Free Water Clearance
ml/min
Time frame: Change from baseline, 4 hours
Whole blood sodium concentration
mmol/L
Time frame: Change from baseline, 4 hours
Whole blood potassium concentration
mmol/L
Time frame: Change from baseline, 4 hours
Whole blood glucose concentration
mg/dl
Time frame: Change from baseline, 4 hours
Whole blood hematocrit
Percentage (%)
Time frame: Change from baseline, 4 hours
Whole blood hemoglobin concentration
g/dl
Time frame: Change from baseline, 4 hours
Serum osmolality
mosmol/kg
Time frame: Change from baseline, 4 hours
Serum copeptin concentration
pmol/L
Time frame: Change from baseline, 4 hours
Serum estrogen
pg/mL
Time frame: Change from baseline, 4 hours
Serum progesterone
ng/mL
Time frame: Change from baseline, 4 hours
Serum follicle stimulating hormone (FSH)
pg/mL
Time frame: Change from baseline, 4 hours
Capillary follicle stimulating hormone (FSH)
MIU/mL
Time frame: At baseline, to determine menstruation status
Salivary Cortisol
ng/mL
Time frame: Change from baseline, 4 hours
Salivary Estradiol
pg/mL
Time frame: Change from baseline, 4 hours
Salivary Progesterone
pg/mL
Time frame: Change from baseline, 4 hours
Low energy availability Questionnaire (LEAF-Q)
Validated questionnaire that assesses injury, gastrointestinal symptoms, and menstrual function, score \> 8 at risk for LEA
Time frame: at screening to determine menstrual history
Menopause Rating Scale (MRS)
5-point likert scale assessing symptoms as none (0) to very severe (4), \> score mean more severe/greater number of symptoms
Time frame: at baseline to determine menopause symptoms
Feeling Scale (FS)
11-point scale assessing changes in mood ranging from very good (5) to very bad (-5), positive score is associated with positive affect
Time frame: change from baseline, 4 hours
Gastrointestinal discomfort and headache (VAS)
100-pt visual analog scale anchored from none (0) to severe (100), \> score is associated with increased symptoms
Time frame: change from baseline, 4 hours
Mental and physical energy and fatigue (VAS)
100-pt visual analog scale anchored from none (0) to severe (100), \> score is associated with stronger feelings
Time frame: change from baseline, 4 hours
Blood Pressure
systolic/diastolic, mm/Hg
Time frame: Change from baseline, 4 hours
Heart Rate
Beats per minute (BPM)
Time frame: Change from baseline, 4 hours
Adverse Events
Documented changes in health and symptoms as a safety measurement
Time frame: Through study completion, an average of 4 weeks for pre- and peri-menopausal subjects and 2 weeks for post-menopausal subjects.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.